Chapman Steven Leonard

About Chapman Steven Leonard

Steve Chapman is the Chief Executive Officer of Natera, Inc., and he also serves on the company’s board of directors. Natera is a publicly traded U.S. diagnostics company focused on genetic testing and cell-free DNA analysis, and Chapman plays a central role in the company’s commercial strategy, operational execution, and broader growth agenda. He has served as CEO since January 2019, following prior leadership roles within Natera, including Chief Operating Officer. Before becoming CEO, Chapman helped guide Natera’s commercial expansion and the scaling of its products across key clinical areas such as oncology, women’s health, and organ health. Under his leadership, Natera has launched and advanced a portfolio of products that includes Signatera, Prospera, Renasight, and Panorama, which have strengthened the company’s position in precision diagnostics. His career at Natera reflects deep experience in bringing genetic-testing technologies to market, building operational teams, and executing growth strategies in a highly specialized healthcare environment. Prior to Natera, Chapman worked at Genzyme Genetics, where he gained experience in medical diagnostics. He began his career as a researcher in the department of human genetics at the University of California, Los Angeles (UCLA), where he designed arrays to identify SNPs associated with multiple sclerosis. That scientific foundation helped shape his later focus on the commercialization of genetic testing and the translation of research into patient-facing diagnostic products. Chapman is also recognized for his leadership in precision medicine and diagnostic innovation. Natera highlights his role in expanding the company’s testing platform and broadening patient access to advanced diagnostic tools. He earned a bachelor’s degree in microbiology, immunology, and molecular genetics from UCLA, graduating with honors. Overall, his background combines scientific training, operational leadership, and executive experience in a complex, regulated life sciences market.